EGFR and lung carcinoma: As our understanding of the molecular biology of lung cancer increases, many mutated targets are being identified, including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, ROS1, BRAF V600E mutation, etc [6,7,27,28].